Portola Pharmaceuticals Inc (PTLA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
William Lis
Employees:
324
270 EAST GRAND AVENUE, SUITE 22, SOUTH SAN FRANCISCO, CA 94080
650-244-6864

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboemboli® in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.415 Billion Shares Outstanding78.484 Million Avg 30-day Volume 2.044 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 0.0 / Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from PTLA instead.

View recent insider trading info

Funds Holding PTLA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PTLA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FENTON DENNIS M

  • Director
No longer subject to file 2020-07-02 0

RENTON HOLLINGS

  • Director
No longer subject to file 2020-07-02 0

LOVE TED W

  • Director
No longer subject to file 2020-07-02 0

STUMP DAVID C

  • Director
No longer subject to file 2020-07-02 0

BIRD JEFFREY W

  • Director
0 2020-07-02 0

WOLFF HENRY WARD

  • Director
No longer subject to file 2020-07-02 0

BREGE LAURA

  • Director
No longer subject to file 2020-07-02 0

JOHNSON JOHN

  • Director
No longer subject to file 2020-07-02 0

GARLAND J. SCOTT PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2020-07-02 0

MORIARTY JOHN B EVP, GENERAL COUNSEL

  • Officer
No longer subject to file 2020-07-02 0

DIER MARDI EVP AND CFO

  • Officer
No longer subject to file 2020-07-02 0

PATNI RAJIV EVP, CMO

  • Officer
No longer subject to file 2020-07-02 0

BRAME GLENN P EVP, CTOO

  • Officer
No longer subject to file 2020-07-02 0

MEYER ERNIE EVP AND CHRO

  • Officer
No longer subject to file 2020-07-02 0

KOENIG SHELDON L. EVP, CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2020-07-02 0

CURNUTTE JOHN T EVP R&D

  • Officer
No longer subject to file 2019-05-17 0

HOMCY CHARLES J

  • FORMER DIRECTOR
No longer subject to file 2019-03-28 0

FU TAO EVP, CBO

  • Officer
77,043 2018-08-31 0

LIS WILLIAM CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
204,448 2018-07-28 0

LAWRENCE JOHN H III SVP, CHIEF MEDICAL OFFICER

  • Officer
6,875 2018-01-31 0

MAXWELL (MAURITIUS) PTE LTD

CAIRNHILL INVESTMENTS (MAURITIUS) PTE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
No longer subject to file 2017-06-01 0

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
6,583,568 2015-12-09 0

GALAKATOS NICHOLAS

  • Director
0 2014-06-27 0

CALIFF ROBERT

  • Director
0 2014-06-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Index Plus All-Cap Fund PTLA -1.0 shares, $-7.13 2020-03-31 N-PORT

Elevate your investments